A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 09 Mar 2023
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lemzoparlimab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors AbbVie
- 06 Jul 2022 Status changed from recruiting to discontinued.
- 02 Dec 2021 Planned number of patients changed from 170 to 163.
- 04 Oct 2021 Planned primary completion date changed from 24 Jul 2025 to 10 Aug 2025.